CJC-1295 with DAC 10mg

CJC-1295 (With DAC) is a synthetic peptide that has been studied for its ability to extend the activity of growth hormone–releasing hormone (GHRH) through drug affinity complex (DAC) binding, resulting in a prolonged half-life reported in research literature to last several days. This extended binding profile has been examined for its ability to sustain growth hormone signaling with reduced dosing frequency in controlled study settings.

Research has evaluated CJC-1295 (With DAC) in relation to cellular growth pathways, tissue repair mechanisms, and biomarkers associated with muscle tissue recovery. Studies have also explored its effects on growth hormone–mediated metabolic processes, including parameters related to body composition, lipid metabolism, and protein synthesis.

Additional investigations have examined its role in growth hormone secretion patterns across different age groups, as well as associations with bone metabolism markers, muscle function indicators, and skin-related structural proteins within experimental models. Research involving age-related declines in growth hormone secretion has assessed GHRH analogs for their potential to influence physiological markers commonly studied in aging research.

Compared to shorter-acting GHRH analogs, the DAC binding component has been studied for its ability to maintain elevated growth hormone signaling over an extended duration, which has been associated in research literature with decreased administration frequency. Safety and tolerability outcomes have been evaluated in clinical and preclinical studies, with findings reported within controlled research environments.

This peptide is supplied as a lyophilized powder to support stability for laboratory and research use.